Accesso libero

Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes

Anze Smole

Anze Smole

Immunology and Cellular Immunotherapy (ICI) Group, Department of Genetic Toxicology and Cancer Biology, National Institute of BiologyLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Smole, Anze
  
13 dic 2022
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Scarica la copertina
Categoria dell'articolo: review
Pubblicato online: 13 dic 2022
Pagine: 409 - 419
Ricevuto: 19 ott 2022
Accettato: 27 ott 2022
DOI: https://doi.org/10.2478/raon-2022-0049
Parole chiave
© 2022 Anze Smole, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

Figure 1

The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor
The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor

Figure 2

Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment
Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment

Figure 3

Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.
Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.
Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicina, Medicina clinica, Medicina interna, Ematologia, Oncologia, Radiologia
Feed RSS della rivista